Literature DB >> 9468341

Hexokinase isoenzymes in normal and cirrhotic human liver: suppression of glucokinase in cirrhosis.

W Lowes1, M Walker, K G Alberti, L Agius.   

Abstract

The activities of hexokinase isoenzymes I-IV (EC 2.7.1.1) and of N-acetylglucosamine kinase (EC 2.7.1.59) were determined in normal human liver and in alcoholic liver disease and primary biliary cirrhosis after FPLC fractionation of high-speed supernatants on Mono-Q with a linear NaCl gradient. In control human liver the hexokinase activities were: I, 3.6; II, 0.7; III, 3.5, IV, 4.8 (mUnits/mg supernatant protein). The activity of N-acetylglucosamine kinase was 8 mU/mg of protein. In alcoholic liver disease and primary biliary cirrhosis, the activity of hexokinase IV (glucokinase) was suppressed to less than 10% of control activity and the activity of hexokinase I was increased 3-fold. The activity of hexokinase II was increased approximately 7-fold in alcoholic liver disease. The activities of hexokinase III and N-acetylglucosamine kinase were unchanged in cirrhosis. Hexokinase III showed 50% substrate inhibition at 100 mM glucose as compared with 0.5mM glucose. The high activity of hexokinase III in human liver (approximately 50% of the low-Km activity and 70% of glucokinase activity) results in a significant underestimation of glucokinase activity as determined by the conventional spectrometric assay while the activity of N-acetylglucosamine kinase may contribute to an overestimation of glucokinase activity in the radiochemical assay. Furthermore glucokinase is dramatically suppressed in liver disease, which although partly compensated for by the increase in hexokinase I (and II), accounts in part for the well-known glucose intolerance of liver cirrhosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9468341     DOI: 10.1016/s0304-4165(97)00092-5

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  5 in total

1.  Dietary fat is a lipid source in 2,3,7,8-tetrachlorodibenzo-ρ-dioxin (TCDD)-elicited hepatic steatosis in C57BL/6 mice.

Authors:  Michelle Manente Angrish; Bryan David Mets; Arthur Daniel Jones; Timothy Richard Zacharewski
Journal:  Toxicol Sci       Date:  2012-04-26       Impact factor: 4.849

2.  Glucokinase links Krüppel-like factor 6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver disease.

Authors:  Lars P Bechmann; Amalia Gastaldelli; Diana Vetter; Gillian L Patman; Laura Pascoe; Rebekka A Hannivoort; Ursula E Lee; Isabel Fiel; Ursula Muñoz; Demetrio Ciociaro; Young-Min Lee; Emma Buzzigoli; Luca Miele; Kei Y Hui; Elisabetta Bugianesi; Alastair D Burt; Christopher P Day; Andrea Mari; Loranne Agius; Mark Walker; Scott L Friedman; Helen L Reeves
Journal:  Hepatology       Date:  2012-03-01       Impact factor: 17.425

3.  Neutrophil Extracellular Traps in Ulcerative Colitis: A Proteome Analysis of Intestinal Biopsies.

Authors:  Tue Bjerg Bennike; Thomas Gelsing Carlsen; Torkell Ellingsen; Ole Kristian Bonderup; Henning Glerup; Martin Bøgsted; Gunna Christiansen; Svend Birkelund; Allan Stensballe; Vibeke Andersen
Journal:  Inflamm Bowel Dis       Date:  2015-09       Impact factor: 5.325

4.  Quercetin and polycystic ovary syndrome, current evidence and future directions: a systematic review.

Authors:  Fatemeh Pourteymour Fard Tabrizi; Fatemeh Hajizadeh-Sharafabad; Maryam Vaezi; Hamed Jafari-Vayghan; Mohammad Alizadeh; Vahid Maleki
Journal:  J Ovarian Res       Date:  2020-01-31       Impact factor: 4.234

Review 5.  Natural products, an important resource for discovery of multitarget drugs and functional food for regulation of hepatic glucose metabolism.

Authors:  Jian Li; Haiyang Yu; Sijian Wang; Wei Wang; Qian Chen; Yanmin Ma; Yi Zhang; Tao Wang
Journal:  Drug Des Devel Ther       Date:  2018-01-10       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.